EVALUATION AT 3 MONTHS OF A COMBINED INTENSE PULSED LIGHT AND PHOTO-BIOMODULATION SYSTEM IN THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION.
Published 2022 - 26th ESCRS Winter Meeting
Reference: P126 | Type: Abstracts | DOI: 10.82333/1qpt-sg38
Authors: Anas-Alexis Benyoussef* 1 , Florian Arzel 1 , Béatrice Cochener 1
1Ophthalmology departement,CHU Brest Morvan,Brest,France
Purpose
Meibomian Gland Dysfunction (MGD) is the leading cause of dry eye syndrome. It is a frequent and under-diagnosed condition with a significant socio-economic impact. We propose here the evaluation of a platform combining pulsed light and photobiomodulation in the treatment of Meibomian gland dysfunction.
Setting
Monocentric prospective cohort conducted in the ophthalmology departement of Brest University Hospital between January 2019 and April 2020.
Methods
In this prospective study, we analysed 74 eyes of 37 patients at 1 month and 3 months after a protocol of 3 Eye-Light® (Espansione Group, Italy) sessions (15 days apart). The primary outcome was the evolution of the OSDI quality of life score. Secondary outcomes were the SPEED questionnaire score, tear breakup time (BUT), Oxford score, non-invasive break up time (NIBUT), lipid layer thickness, lacrimal meniscus height and Meibomian gland atrophy rate. Tolerance of the treatment was also evaluated.
Results
We found a significant improvement in OSDI scores at 1 month (-17.32; 95% CI (-25.84; -8.79), p<0.0001) and 3 months (-16.95; 95% CI (-25.26; -8.64), p<0.0001). The SPEED score, BUT, Oxford score, Meibomian gland atrophy and NIBUT were also statistically improved. Tolerance to treatment was very good despite two cases of herpetic keratitis, which were resolved under treatment.
Conclusion
Treatment with the Eye-Light® in three sessions every two weeks significantly reduced symptoms and ocular surface damage in patients with MGD. This data suggests that the use of Eye-Light® may represent a good option for patients with MGD.